Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

A Sleeping Beauty transposon-mediated screen identifies murine susceptibility genes for adenomatous polyposis coli (Apc)-dependent intestinal tumorigenesis.

Starr TK, Scott PM, Marsh BM, Zhao L, Than BL, O'Sullivan MG, Sarver AL, Dupuy AJ, Largaespada DA, Cormier RT.

Proc Natl Acad Sci U S A. 2011 Apr 5;108(14):5765-70. doi: 10.1073/pnas.1018012108. Epub 2011 Mar 21.

2.

Targeted deletion of liver glucose-6 phosphatase mimics glycogen storage disease type 1a including development of multiple adenomas.

Mutel E, Abdul-Wahed A, Ramamonjisoa N, Stefanutti A, Houberdon I, Cavassila S, Pilleul F, Beuf O, Gautier-Stein A, Penhoat A, Mithieux G, Rajas F.

J Hepatol. 2011 Mar;54(3):529-37. doi: 10.1016/j.jhep.2010.08.014. Epub 2010 Oct 1.

PMID:
21109326
3.

PiggyBac transposon mutagenesis: a tool for cancer gene discovery in mice.

Rad R, Rad L, Wang W, Cadinanos J, Vassiliou G, Rice S, Campos LS, Yusa K, Banerjee R, Li MA, de la Rosa J, Strong A, Lu D, Ellis P, Conte N, Yang FT, Liu P, Bradley A.

Science. 2010 Nov 19;330(6007):1104-7. doi: 10.1126/science.1193004. Epub 2010 Oct 14.

4.

Reprogramming the posttranslational code of SRC-3 confers a switch in mammalian systems biology.

York B, Yu C, Sagen JV, Liu Z, Nikolai BC, Wu RC, Finegold M, Xu J, O'Malley BW.

Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):11122-7. doi: 10.1073/pnas.1005262107. Epub 2010 Jun 1.

5.

Genome-wide mapping and assembly of structural variant breakpoints in the mouse genome.

Quinlan AR, Clark RA, Sokolova S, Leibowitz ML, Zhang Y, Hurles ME, Mell JC, Hall IM.

Genome Res. 2010 May;20(5):623-35. doi: 10.1101/gr.102970.109. Epub 2010 Mar 22.

6.

Mouse models of hepatocellular carcinoma.

Fausto N, Campbell JS.

Semin Liver Dis. 2010 Feb;30(1):87-98. doi: 10.1055/s-0030-1247135. Epub 2010 Feb 19. Review.

PMID:
20175036
7.

Whole-body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality.

Collier LS, Adams DJ, Hackett CS, Bendzick LE, Akagi K, Davies MN, Diers MD, Rodriguez FJ, Bender AM, Tieu C, Matise I, Dupuy AJ, Copeland NG, Jenkins NA, Hodgson JG, Weiss WA, Jenkins RB, Largaespada DA.

Cancer Res. 2009 Nov 1;69(21):8429-37. doi: 10.1158/0008-5472.CAN-09-1760. Epub 2009 Oct 20.

8.

BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells.

Mani M, Carrasco DE, Zhang Y, Takada K, Gatt ME, Dutta-Simmons J, Ikeda H, Diaz-Griffero F, Pena-Cruz V, Bertagnolli M, Myeroff LL, Markowitz SD, Anderson KC, Carrasco DR.

Cancer Res. 2009 Oct 1;69(19):7577-86. doi: 10.1158/0008-5472.CAN-09-0773. Epub 2009 Sep 8.

9.

A genome-wide RNAi screen identifies a new transcriptional module required for self-renewal.

Hu G, Kim J, Xu Q, Leng Y, Orkin SH, Elledge SJ.

Genes Dev. 2009 Apr 1;23(7):837-48. doi: 10.1101/gad.1769609.

10.

Transcription factor Zfx controls BCR-induced proliferation and survival of B lymphocytes.

Arenzana TL, Smith-Raska MR, Reizis B.

Blood. 2009 Jun 4;113(23):5857-67. doi: 10.1182/blood-2008-11-188888. Epub 2009 Mar 27.

11.

A transposon-based genetic screen in mice identifies genes altered in colorectal cancer.

Starr TK, Allaei R, Silverstein KA, Staggs RA, Sarver AL, Bergemann TL, Gupta M, O'Sullivan MG, Matise I, Dupuy AJ, Collier LS, Powers S, Oberg AL, Asmann YW, Thibodeau SN, Tessarollo L, Copeland NG, Jenkins NA, Cormier RT, Largaespada DA.

Science. 2009 Mar 27;323(5922):1747-50. doi: 10.1126/science.1163040. Epub 2009 Feb 26.

12.

A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma.

Keng VW, Villanueva A, Chiang DY, Dupuy AJ, Ryan BJ, Matise I, Silverstein KA, Sarver A, Starr TK, Akagi K, Tessarollo L, Collier LS, Powers S, Lowe SW, Jenkins NA, Copeland NG, Llovet JM, Largaespada DA.

Nat Biotechnol. 2009 Mar;27(3):264-74. doi: 10.1038/nbt.1526. Epub 2009 Feb 22.

13.

Absence of the SRC-2 coactivator results in a glycogenopathy resembling Von Gierke's disease.

Chopra AR, Louet JF, Saha P, An J, Demayo F, Xu J, York B, Karpen S, Finegold M, Moore D, Chan L, Newgard CB, O'Malley BW.

Science. 2008 Nov 28;322(5906):1395-9. doi: 10.1126/science.1164847.

14.

An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer.

Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, Ma B, Zender P, Kubicka S, Luk JM, Schirmacher P, McCombie WR, Wigler M, Hicks J, Hannon GJ, Powers S, Lowe SW.

Cell. 2008 Nov 28;135(5):852-64. doi: 10.1016/j.cell.2008.09.061. Epub 2008 Nov 13.

15.

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses.

Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW.

Science. 2008 Sep 26;321(5897):1801-6. doi: 10.1126/science.1164368. Epub 2008 Sep 4.

16.

Modelling Myc inhibition as a cancer therapy.

Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, Karnezis AN, Swigart LB, Nasi S, Evan GI.

Nature. 2008 Oct 2;455(7213):679-83. doi: 10.1038/nature07260. Epub 2008 Aug 17.

17.

Sorafenib in liver cancer--just the beginning.

Roberts LR.

N Engl J Med. 2008 Jul 24;359(4):420-2. doi: 10.1056/NEJMe0802241. No abstract available.

PMID:
18650519
18.

The function of BCL9 in Wnt/beta-catenin signaling and colorectal cancer cells.

de la Roche M, Worm J, Bienz M.

BMC Cancer. 2008 Jul 15;8:199. doi: 10.1186/1471-2407-8-199.

19.

Down-regulation of ATBF1 is a major inactivating mechanism in hepatocellular carcinoma.

Kim CJ, Song JH, Cho YG, Cao Z, Lee YS, Nam SW, Lee JY, Park WS.

Histopathology. 2008 Apr;52(5):552-9. doi: 10.1111/j.1365-2559.2008.02980.x. Epub 2008 Feb 23.

PMID:
18312352
20.

Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma.

Kim W, Yoon JH, Jeong JM, Cheon GJ, Lee TS, Yang JI, Park SC, Lee HS.

Mol Cancer Ther. 2007 Sep;6(9):2554-62.

Supplemental Content

Support Center